3 Places That Actually Offer GLP-1 Microdosing (And What It Actually Costs)

What does "GLP-1 microdosing" actually mean?

Ask five different sources for a definition of GLP-1 microdosing and you'll get five different answers — and that's not a knock on any of them, it's the actual state of the term. A Harvard endocrinologist, Dr. Jody Dushay, told STAT News in May 2026 that there isn't a single agreed-upon definition of microdosing in this context, and the reporting bears that out: the word gets used for at least two distinct things that keep getting mashed together online.

The first is a provider-run option: a telehealth platform sells a compounded GLP-1 formulated at a lower dose, or keeps you on the early rungs of the standard titration ladder longer than usual, under an actual prescriber's supervision. The second is a much looser, largely self-directed practice — splitting an FDA-approved pen into smaller shots, stretching a compounded vial across more weeks than prescribed, or buying a "microdosing kit" from an online seller — usually chasing either a lower price, fewer side effects, or claimed wellness benefits that have nothing to do with weight loss. A 2025 survey by the health-tracking app Evidation found roughly one in seven GLP-1 users had tried some version of this, and close to half did it without telling a doctor.

Where is GLP-1 microdosing actually offered — is there a real provider?

Most of what circulates about GLP-1 microdosing has no provider attached to it at all — it's a Reddit thread, a TikTok testimonial, or a friend's script for splitting her own pen. Very few licensed telehealth platforms have built an actual, named, priced product around the word. As of mid-2026, three are worth naming specifically, and they don't all mean the same thing by "microdose."

• Mochi Health lists microdose as one of four semaglutide formats (alongside standard injection, oral tablet, and oral drops), all covered by the same flat $99/mo medication fee. It's less a separate product than the low end of the same titration range, run through the same obesity-medicine physician network.
• Fridays has built out a genuinely distinct "Microdosing" section of its site, separate from its weight-loss program, using sub-therapeutic compounded semaglutide or tirzepatide combined with other ingredients and positioned around energy, metabolic balance, and general wellness rather than pounds lost.
• Noom sells a "Microdose GLP-1Rx" program as its own line item, distinct from Noom Med's standard $249/mo GLP-1Rx tier, defined internally as 25% or less of a typical maintenance dose and still framed around weight loss.

All three are nationwide US telehealth services, not local clinics — "near me" isn't really the right frame here. Availability depends on which states each platform is licensed in, not your zip code.

What does GLP-1 microdosing cost — and why isn't there a bigger price table?

Compare this to a standard cheapest GLP-1 comparison, which stacks up seven or eight providers, and the table above looks thin on purpose. That's honest, not lazy. GLP-1 microdosing is a young, inconsistently labeled corner of a fast-moving market — most of the activity happens outside any priced, named product, which means most of it simply can't be put in a comparison table without inventing numbers that don't exist.

Of the three real options, Mochi Health's is the least like a distinct "microdose" product and the most like a slower titration choice inside its normal flat-rate plan — you're not paying more or less to pick it. Fridays and Noom both built genuinely separate microdose product pages with their own pricing and their own marketing language, which is why their numbers sit apart from their standard GLP-1 tiers. None of these three prices covers labs, and all three require a compounded (not FDA-approved) medication — a status worth understanding before you enroll, covered in more depth below.

How does the microdosing protocol actually work?

The FDA-approved Wegovy schedule is the reference point here: a five-step climb from 0.25mg weekly up to a 2.4mg maintenance dose over at least 16 weeks, detailed in full in our semaglutide dosage guide. "Microdosing," in the provider-run sense, generally means staying at or near the earliest, lowest rungs of that ladder — the doses the FDA label itself classifies as initiation and tolerability steps, not approved maintenance doses — for longer than the standard schedule calls for, or indefinitely.

Noom's own definition puts a number on it: 25% or less of a typical maintenance dose. Mochi's compounded semaglutide range runs from 0.22mg to 2.67mg weekly, and its microdose format sits at the low end of that same range rather than following a separate dosing chart. In every legitimate version of this, a prescriber sets and adjusts the dose — none of these platforms hand you a fixed microdosing chart to self-administer.

Does the science actually back microdosing, or is this mostly Reddit talk?

Mostly the latter, at least for now. Dr. Jody Dushay, the Harvard endocrinologist quoted above, told STAT News in May 2026 that microdosing GLP-1s isn't a well-established practice and that there's no legitimate long-term data behind it. That's a strong statement from someone who treats patients with these drugs daily, and it lines up with the broader clinical literature: the trials that established semaglutide and tirzepatide's benefits — STEP-1 for semaglutide, SURMOUNT-1 for tirzepatide — were built around a clear dose-response relationship, where more of the drug, up to the approved maintenance dose, produced more weight loss. Deliberately staying well below that dose wasn't the protocol those trials tested.

At least one clinical trial has now been registered specifically to study microdosed GLP-1 for health, quality-of-life, and longevity outcomes — a sign the question is finally being asked formally. It hasn't reported results. Until it does, "microdosing works" and "microdosing is gentler" remain claims resting on anecdote and marketing copy, not published trial data.

Is a lower dose gentler — and does it still work?

The gentler-side-effects pitch is intuitive, but it's not obviously true in practice. Dr. Ritu Anand, an endocrinologist quoted by Hackensack Meridian Health in May 2026, cautioned that microdosing can backfire: rather than side effects fading gradually the way they would on a standard titration, they can return just as intensely with each new small injection, because the body never fully adapts to a moving, sub-therapeutic target. Noom's own marketing cites a self-reported figure — about 70% of its microdose members reporting no side effects — but that's company data from its own user base, not an independent trial, and self-reported side-effect data tends to run more favorable than clinical measurement.

On effectiveness, the honest answer is: probably less, and less predictably. The weight-loss and metabolic benefits documented in the major trials were measured at the approved maintenance doses. Staying below that ceiling long-term is an off-label choice, and while some people do lose weight or feel appetite changes at lower doses, the evidence base for how much benefit holds up at a fraction of the studied dose is thin. That's a tradeoff to weigh with your prescriber, not a settled fact in either direction.

Can GLP-1 microdosing help with autoimmune or inflammatory conditions?

This is the part of the trend that deserves the most skepticism, and it's worth treating as an open question rather than a benefit list. GLP-1 receptors do exist on immune cells, and animal and cell-culture studies have shown these drugs can lower inflammatory markers like TNF-alpha, IL-6, and IL-1beta. That's real mechanistic science — and it's a long way from a treatment for rheumatoid arthritis, lupus, Hashimoto's, or any other autoimmune condition in an actual person. There is no completed human clinical trial showing GLP-1 microdosing improves an autoimmune or inflammatory disease outcome as of this writing.

Even Fridays, the one named provider whose microdosing product leans hardest into wellness language — energy, metabolic balance, inflammation, cognitive clarity — states plainly on its own product page that those specific benefits have not been specifically studied for its compounded formulations. That's a useful tell: when the company selling the product tells you the claim is unstudied, believe them.

Is microdosing the right starting point for me in perimenopause?

If you're GI-sensitive already — and perimenopause has a way of making nausea and bloating feel like unwelcome roommates — the appeal of starting lower and moving slower makes sense. A gentler ramp genuinely can mean fewer of the early nausea episodes that push some women to quit a GLP-1 in the first few weeks, and pacing weight loss more slowly has a side benefit worth knowing about: it tends to be easier on muscle, which matters more once estrogen decline is already chipping away at lean mass. We go deeper on that specific tradeoff in GLP-1 and muscle loss in perimenopause.

The honest counterweight: choosing to stay at a lower dose trades some certainty about results for that gentler start. If your main goal is meaningful weight or metabolic change, a standard titration toward the studied maintenance dose has the stronger evidence behind it. A slower climb toward that same maintenance dose — not necessarily stopping short of it — is a middle path worth raising with your prescriber if side effects, not the destination, are your concern.

How to tell a legitimate low-dose protocol from a DIY red flag

The line that matters most isn't the dose — it's who's managing it. A legitimate low-dose protocol comes from a licensed prescriber, filled through a named 503A compounding pharmacy, with a dose your provider set and can adjust. A red flag looks different: splitting an FDA-approved pen yourself, buying a "microdosing kit" from an unnamed online seller, or drawing your own doses from a vial without a provider's specific instructions.

Eli Lilly has stated that its Zepbound and Mounjaro pens and single-dose vials are approved for single use only and aren't preserved for repeated draws — splitting them, the company warns, raises real contamination risk. The FDA has backed that concern with data: a July 2024 alert on compounded semaglutide dosing errors documented patients accidentally injecting five to twenty times their intended dose after confusing units on a syringe, some requiring hospitalization. And in March 2026, the FDA sent 30 warning letters to telehealth companies over unsubstantiated and misleading marketing claims about compounded GLP-1 products generally — a reminder that this whole category is under active regulatory scrutiny, and that a bold claim on a landing page isn't the same as FDA evidence. If a seller can't name its compounding pharmacy or a prescriber who's actually reviewed your history, that's the moment to walk away, not adjust the dose yourself.